These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1331205)

  • 1. Plasma bactericidal activity of a new C-5 methyl fluoroquinolone after oral doses of 400 and 800 mg.
    Gu JW; Fang W; Neu HC
    J Clin Pharmacol; 1992 Sep; 32(9):804-7. PubMed ID: 1331205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria.
    Wakebe H; Mitsuhashi S
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2185-91. PubMed ID: 1332589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections.
    Wakebe H; Imada T; Yoneda H; Mukai F; Ohguro K; Ohmori K; Tamaoka H; Yabuuchi Y
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2340-5. PubMed ID: 7840567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of OPC-17116.
    Neu HC; Fang W; Gu JW; Chin NX
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1310-5. PubMed ID: 1329620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Apr; 31(4):497-504. PubMed ID: 8390433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activity, morphological alterations, and synergistic interactions of rufloxacin, a new fluoroquinolone, alone and in combination with its N-desmethylate D derivative (MF 922).
    Marchese A; Debbia EA; Pesce A; Schito GC
    Chemotherapy; 1996; 42(2):90-9. PubMed ID: 8697894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic characteristics of prulifloxacin.
    Matera MG
    Pulm Pharmacol Ther; 2006; 19 Suppl 1():20-9. PubMed ID: 16360331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinolone.
    Bremm KD; Petersen U; Metzger KG; Endermann R
    Chemotherapy; 1992; 38(6):376-87. PubMed ID: 1288961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
    Harnett SJ; Fraise AP; Andrews JM; Jevons G; Brenwald NP; Wise R
    J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in-vitro activity of two new quinolones: rufloxacin and MF 961.
    Wise R; Andrews JM; Matthews R; Wolstenholme M
    J Antimicrob Chemother; 1992 Jun; 29(6):649-60. PubMed ID: 1324239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
    Araake M; Hara T; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a.
    Morrissey I; Smith JT
    J Med Microbiol; 1995 Jul; 43(1):4-8. PubMed ID: 7608954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms.
    Felmingham D
    J Antimicrob Chemother; 2000 Mar; 45():1-8. PubMed ID: 10719006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grepafloxacin--a new fluoroquinolone.
    Med Lett Drugs Ther; 1998 Jan; 40(1019):17-8. PubMed ID: 9465856
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
    McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
    Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the bactericidal activity of temafloxacin.
    Jacobs MR
    Am J Med; 1991 Dec; 91(6A):31S-34S. PubMed ID: 1662893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
    Inoue M; Kuga A; Kaieda S; Hosaka M; Kitasato H; Sato Y; Okamoto R; Eda T; Hoshino K; Seto I
    Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
    Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.